Xampla secures £11m to replace plastics

Xampla secures £11m to replace plastics

Xampla secures $14 million to replace plastics with plant-based alternatives. UK-based Xampla, a University of Cambridge spin-out, raised $14 million to scale its plant-based materials, aiming to replace billions of single-use plastic items over the next five years. The funding will support expansion into Asia Pacific and Europe….


UK materials innovation company Xampla has announced the successful raise of US$14 million in a Series A investment round. The funding will be utilised to scale its technology, designed to replace billions of single-use plastic items with plant-based alternatives.

Plastic pollution remains a significant environmental challenge, as plastic does not fully biodegrade but instead breaks into smaller fragments, accumulating in ecosystems and posing threats to wildlife and public health. Xampla, a spin-out from the University of Cambridge, has developed Morro materials, a natural polymer alternative derived from regenerative plant proteins. These materials are plastic-free, biodegradable, home compostable, and exempt from the EU’s Single-Use Plastic Directive (SUPD). According to the company, Morro materials aim to address the global plastic waste crisis, with approximately 400 million tonnes of plastic waste generated annually and less than 10% being recycled.

The new capital injection is projected to enable Xampla’s materials to replace more than 10 billion single-use plastic items over the next five years. Xampla’s CEO, Alexandra French, expressed confidence in the company’s potential, stating that the funding represents a significant endorsement of their innovative solutions. The company plans to expand its operations in the Asia Pacific region and further grow in the UK and Europe.

In the coming years, Morro materials are expected to replace plastics in applications such as linings for takeaway boxes, coffee cups, and sachets. Unlike conventional plastics, Morro Coating allows cardboard to remain recyclable while providing protection against grease, oxygen, and moisture.

The funding round was led by Emerald Technology Ventures, a venture fund focused on sustainable packaging. Neil Cameron, leading Emerald’s sustainable packaging investment fund, highlighted the global potential of Xampla’s technology, noting the significant growth forecast for the barrier coatings market.

Other participants in the Series A round included BGF, one of the largest growth capital investors in the UK and Ireland, Munich-based Matterwave Ventures, as well as existing investors Amadeus Capital Partners and Horizons Ventures. The funding is expected to facilitate the expansion of Xampla’s partnerships and global reach as it scales the production of Morro materials to combat some of the most polluting plastics worldwide.

Rowan Bird, Investor at BGF, praised Xampla’s technology for its scalability and practicality as an alternative to plastic, emphasizing its compatibility with existing manufacturing lines and its appeal to brands seeking sustainable solutions.



  • Foreverland raises €6m for Europe push

    Foreverland raises €6m for Europe push

    Foreverland is scaling cocoa-free chocolate across Europe after fresh funding. The Italian foodtech company has raised €6 million to expand Choruba, deepen manufacturer partnerships, and support a new organic product line.


  • Durham study exposes multiple-job protection gaps

    Durham study exposes multiple-job protection gaps

    Multiple-job workers face widening gaps in dignity protections at work. New research argues current frameworks miss the realities of precarious multiple employment, leaving essential workers exposed to stress, stigma, and weak workplace protections.


  • New training targets autoimmune workplace blind spot

    New training targets autoimmune workplace blind spot

    Autoimmune illness is emerging as a major workplace risk nationwide. A new CPD-accredited training programme is aiming to help employers and healthcare professionals recognise autoimmune disease earlier and respond with more effective support.